Effects of Descurainia sophia on Oxidative Stress Markers and Thirst Alleviation in Hemodialysis Patients: A Randomized Double-Blinded Placebo-Controlled Cross-Over Clinical Trial
Table 4
The comparison of outcomes between placebo and treatment for different sequence.
Group I (DS administration followed by placebo)
Group II (placebo followed by DS administration)
Study groups
DS
Placebo
value
Study groups
Placebo
DS
value
Thirst score
DS-placebo
6.6 ± .76
9.8 ± 0.93
<0.001
Placebo-DS
9.7 ± 0.78
8.2 ± 0.76
<0.001
Potassium (mEq/L)
DS-placebo
5.57 ± 0.75
5.50 ± 0.58
0.418
Placebo-DS
5.51 ± 0.79
5.59 ± 0.80
0.586
Cholesterol (mg/dl)
DS-placebo
138.33 ± 46.41
143.65 ± 39.29
0.302
Placebo-DS
139.36 ± 45.38
137.48 ± 43.90
0.819
Calcium (mg/dl)
DS-placebo
8.34 ± 0.46
8.23 ± 0.39
0.391
Placebo-DS
8.25 ± 0.66
8.39 ± 0.83
0.408
Triglycerides (mg/dl)
DS-placebo
163.95 ± 105.11
155.91 ± 94.70
0.502
Placebo-DS
170.38 ± 94.23
154.15 ± 89.08
0.334
Na
DS-placebo
141.43 ± 6.24
137.05 ± 2.81
<0.001
Placebo-DS
134.93 ± 4.02
134.25 ± 3.26
0.414
OXLDL
DS-placebo
1266.95 ± 675.84
1215.54 ± 671.68
0.525
Placebo-DS
1377.33 ± 809.73
1011.04 ± 556.21
0.005
ANT
DS-placebo
1.14 ± 0.70
0.84 ± 0.61
<0.001
Placebo-DS
0.71 ± 0.42
1.34 ± 0.59
<0.001
Malondialdehyde (μmol/L)
DS-placebo
1687 ± 402
946 ± 567
<0.001
Placebo-DS
997 ± 468
1578 ± 668
0.0005
TAC (mmol trolox equiv./L)
DS-placebo
0.97 ± 0.43
0.78 ± 0.38
0.093
Placebo-DS
0.83 ± 0.32
1.06 ± 0.49
0.046
Values are expressed as means ± SD; the drug-placebo group took the drug at first, while the placebo-DS group received a placebo following DS. The paired t-test was used to compare the outcomes change between DS (pre + post values) and placebo (pre + post values) in each study group. DS, Descurainia sophia.
